{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:59:31Z","timestamp":1782316771949,"version":"3.54.5"},"reference-count":25,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Women's Health"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>This retrospective database analysis describes clinical characteristics and treatment patterns of U.S. women with a diagnosis for uterine fibroids (UF), both with and without heavy menstrual bleeding (HMB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      Two cohorts aged 18\u201350 years with an incident UF diagnosis, comprising women with and without claims for HMB (UF-HMB and UF-only), were identified from the IQVIA PharMetrics\n                      <jats:sup>\u00ae<\/jats:sup>\n                      Plus database (January 1, 2010\u2013December 31, 2019). The index date was the first UF claim following diagnosis; treatment patterns were documented for postindex years 1 and 2 and the full duration of postindex follow-up. Also identified were claims for symptoms or signs potentially associated with UF. Outcomes were the proportion of patients treated with pharmacologic therapies of interest and gynecologic procedures. Logistic regression was used to identify factors associated with postdiagnosis hysterectomy and hormonal therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 66,313 (71.8%) women were included in the UF-HMB cohort (mean age [standard deviation]) 42.6 [5.4] years), and 26,068 (28.2%) in the UF-only cohort (41.8 [6.3]). Median follow-up was \u223c4 years. Pain was the most common symptom (42.7% in patients with UF-HMB and 36.6% with UF-only); also common were abnormal bleeding (15.6%, 11.5%) and fatigue (22.2%, 15.5%). Within 1 year of UF diagnosis, 28.8% and 49.2% of women with UF-HMB and UF-only, respectively, had no claims for relevant pharmacologic or surgical treatment. In logistic regression, multiple factors were associated with a higher likelihood of receiving hysterectomy or hormonal therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Patients with UF-HMB were more likely to receive UF treatment, either surgical or pharmacologic, than women with UF-only. Apart from HMB, pain was the most commonly documented symptom of UF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jwh.2022.0056","type":"journal-article","created":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T09:04:45Z","timestamp":1669107885000},"page":"332-340","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Treatment Patterns in Patients with Uterine Fibroids With and Without a Diagnosis of Heavy Menstrual Bleeding: Results from a Large U.S. Claims Database"],"prefix":"10.1177","volume":"32","author":[{"given":"Laura","family":"McKain","sequence":"first","affiliation":[{"name":"Medical Affairs, Myovant Sciences, Inc., Brisbane, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Edsall","sequence":"additional","affiliation":[{"name":"Life Sciences Practice, Charles River Associates, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Dufour","sequence":"additional","affiliation":[{"name":"Medical Affairs, Myovant Sciences, Inc., Brisbane, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Lickert","sequence":"additional","affiliation":[{"name":"Medical Affairs, Myovant Sciences, Inc., Brisbane, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.99"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.14640"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1607264"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.09.1280"},{"issue":"2","key":"e_1_3_6_6_2","first-page":"100","article-title":"Uterine fibroids: Diagnosis and treatment","volume":"95","author":"De La Cruz MS","year":"2017","unstructured":"De La Cruz MS, , Buchanan EM. Uterine fibroids: Diagnosis and treatment. Am Fam Physician, 2017; 95(2):100\u2013107. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28084714.","journal-title":"Am Fam Physician"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S51083"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2414609"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6874-12-6"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/GRF.0000000000000164"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.4293\/JSLS.2017.00041"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S138982"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004401"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008283"},{"key":"e_1_3_6_15_2","unstructured":"MYFEMBREE\u00ae (relugolix estradiol and norethindrone acetate) tablets for oral use [prescribing information]. Brisbane CA: Myovant Sciences Inc.; 2021."},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904351"},{"key":"e_1_3_6_17_2","unstructured":"US Food and Drug Administration (FDA). FDA approves new option to treat heavy menstrual bleeding associated with fibroids in women 2020. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-option-treat-heavy-menstrual-bleeding-associated-fibroids-women [Last accessed: June 15 2021]."},{"key":"e_1_3_6_18_2","author":"Duckitt K","year":"2012","unstructured":"Duckitt K, , Collins S. Menorrhagia. BMJ Clin Evid, 2012;2012(0805).","journal-title":"BMJ Clin Evid"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-020-01005-6"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.43"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2020.8983"},{"key":"e_1_3_6_22_2","unstructured":"Marth MP De AP Roach A. Support Your Clinical and Economic Value Proposition with Real World Data - Part 2 in a Series. IQVIA website. Published March 24 2021. Available from: https:\/\/www.iqvia.com\/locations\/united-states\/blogs\/2021\/03\/support-clinical-economic-value-prop-with-rwd-part-2 [Last accessed: July 15 2022]."},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/pop.2017.0151"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1372107"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2017.10.001"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1701-2163(15)30338-8"}],"container-title":["Journal of Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jwh.2022.0056","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jwh.2022.0056","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jwh.2022.0056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:56:55Z","timestamp":1777658215000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jwh.2022.0056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1089\/jwh.2022.0056"],"URL":"https:\/\/doi.org\/10.1089\/jwh.2022.0056","relation":{},"ISSN":["1540-9996","1931-843X"],"issn-type":[{"value":"1540-9996","type":"print"},{"value":"1931-843X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}